PTC Therapeutics, Inc. hosted a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, NJ.
 
PTC’s Hopewell facility is approximately 220,500 sq.-ft. of office, manufacturing and laboratory space, including state-of-the-art technology equipped to handle process development and manufacturing of plasmids and adeno-associated virus (AAV) vectors. The company is also offering world class plasmid DNA and AAV manufacturing services to external partners. PTC’s in-house manufacturing, research and development capabilities promote maximum control over the quality, capacity, supply and seamless transition from clinical to commercial development.
 
“We are committed to being an innovation-based company that brings the best therapies to patients with rare diseases,” said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. “Gene therapy holds tremendous promise to treat intractable rare genetic disorders. We have built our capabilities to both perform gene therapy research and to manufacture these biological products. We are proud to have such a talented team and state-of-the-art manufacturing facility here in Hopewell, N.J. that will help expedite bringing these therapies to patients.”
 
The Hopewell gene therapy manufacturing center complements PTC’s existing operations at the Company’s global headquarters in South Plainfield, NJ and brings the total number of New Jersey-based employees to 625.